SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Authors
Keywords
SARS-CoV-2 variants, COVID-19, neutralizing antibodies, vaccines, monoclonal antibodies, B.1.1.7, Moderna, Novavax
Journal
Cell Host & Microbe
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-07
DOI
10.1016/j.chom.2021.03.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021
- (2021) Summer E. Galloway et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Novavax offers first evidence that COVID vaccines protect people against variants
- (2021) Ewen Callaway et al. NATURE
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
- (2021) Alexander Muik et al. SCIENCE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- (2020) Yan Wu et al. SCIENCE
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
- (2020) Qianqian Li et al. CELL
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
- (2020) Bette Korber et al. CELL
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
- (2020) Fabian Schmidt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies
- (2020) Kshitij Wagh et al. Current Opinion in HIV and AIDS
- Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
- (2020) Leonid Yurkovetskiy et al. CELL
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide
- (2020) Sandra Isabel et al. Scientific Reports
- D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
- (2020) Drew Weissman et al. Cell Host & Microbe
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNT version 1.5, including a full implementation of phylogenetic morphometrics
- (2016) Pablo A. Goloboff et al. CLADISTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started